400 related articles for article (PubMed ID: 19944126)
21. Characterization of the LOAEL-to-NOAEL uncertainty factor for mild adverse effects from acute inhalation exposures.
Alexeeff GV; Broadwin R; Liaw J; Dawson SV
Regul Toxicol Pharmacol; 2002 Aug; 36(1):96-105. PubMed ID: 12383722
[TBL] [Abstract][Full Text] [Related]
22. The significance of excursions above the ADI: duration in relation to pivotal studies.
Walker R
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S114-8. PubMed ID: 10597624
[TBL] [Abstract][Full Text] [Related]
23. Review of the U.S. Army's health risk assessments for oral exposure to six chemical-warfare agents. Introduction.
J Toxicol Environ Health A; 2000 Mar; 59(5-6):281-526. PubMed ID: 10742829
[TBL] [Abstract][Full Text] [Related]
24. Non-cancer risk assessment for nickel compounds: issues associated with dose-response modeling of inhalation and oral exposures.
Haber LT; Allen BC; Kimmel CA
Toxicol Sci; 1998 Jun; 43(2):213-29. PubMed ID: 9710963
[TBL] [Abstract][Full Text] [Related]
25. Metabolism, variability and risk assessment.
Dorne JL
Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
[TBL] [Abstract][Full Text] [Related]
26. Health effects classification and its role in the derivation of minimal risk levels: neurological effects.
Chou CH; Williams-Johnson M
Toxicol Ind Health; 1998; 14(3):455-71. PubMed ID: 9569449
[TBL] [Abstract][Full Text] [Related]
27. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of acute inhalation toxicity for chemicals with limited toxicity information.
Grant RL; Kadlubar BJ; Erraguntla NK; Honeycutt M
Regul Toxicol Pharmacol; 2007 Apr; 47(3):261-73. PubMed ID: 17275156
[TBL] [Abstract][Full Text] [Related]
29. Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for acetone.
Gentry PR; Covington TR; Clewell HJ; Anderson ME
J Toxicol Environ Health A; 2003 Dec; 66(23):2209-25. PubMed ID: 14612334
[TBL] [Abstract][Full Text] [Related]
30. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
Dorne JL
Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
[TBL] [Abstract][Full Text] [Related]
31. Methods for deriving pesticide aquatic life criteria.
TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel uncertainty factors and thresholds of toxicological concern for health hazard and risk assessment: Application to cleaning product ingredients.
Wang Z; Scott WC; Williams ES; Ciarlo M; DeLeo PC; Brooks BW
Environ Int; 2018 Apr; 113():357-376. PubMed ID: 29452931
[TBL] [Abstract][Full Text] [Related]
33. Critical review of the human data on short-term nitrogen dioxide (NO2) exposures: evidence for NO2 no-effect levels.
Hesterberg TW; Bunn WB; McClellan RO; Hamade AK; Long CM; Valberg PA
Crit Rev Toxicol; 2009; 39(9):743-81. PubMed ID: 19852560
[TBL] [Abstract][Full Text] [Related]
34. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of inhalation TTC values with the database RepDose.
Escher SE; Tluczkiewicz I; Batke M; Bitsch A; Melber C; Kroese ED; Buist HE; Mangelsdorf I
Regul Toxicol Pharmacol; 2010 Nov; 58(2):259-74. PubMed ID: 20600457
[TBL] [Abstract][Full Text] [Related]
36. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose.
Simmons JE; Evans MV; Boyes WK
J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):927-50. PubMed ID: 16020185
[TBL] [Abstract][Full Text] [Related]
37. Quantitative approaches to human risk assessment for noncancer health effects.
Kimmel CA
Neurotoxicology; 1990; 11(2):189-98. PubMed ID: 2234540
[TBL] [Abstract][Full Text] [Related]
38. A quantitative comparison of points of departure between 28-day and 90-day repeated dose studies with a proposed extrapolation factor.
Lampe BJ; Fuller E; Kuppusamy SP
Regul Toxicol Pharmacol; 2018 Feb; 92():189-200. PubMed ID: 29242155
[TBL] [Abstract][Full Text] [Related]
39. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
[TBL] [Abstract][Full Text] [Related]
40. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
